{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T01:21:19Z","timestamp":1791681679303,"version":"4.3.4"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Advances in Rehabilitation Science and Practice"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Rationale:<\/jats:title>\n                    <jats:p>Paired vagus nerve stimulation (VNS) has emerged as a safe and effective therapy to reduce upper limb (UL) motor deficits and improve motor function in individuals with chronic ischemic stroke with moderate-to-severe arm impairment. VNS paired with rehabilitation motor tasks led by an occupational or physical therapist is typically done in-clinic during initial treatment. Attending regular outpatient sessions can be difficult for individuals with limited mobility\/transportation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The primary objective of the VNS-REHAB At-Home study is to assess the feasibility, safety, compliance, and therapist\/patient acceptance of delivering up to 36\u2009hours of therapist-activated VNS paired with UL rehabilitation in a home setting. Secondary objectives include evaluating improvements in UL impairment and function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Design:<\/jats:title>\n                    <jats:p>The acute stage is therapist-activated VNS therapy paired with at home rehabilitation in 1- to 2-hour sessions up to 5 times per week for up to 18\u2009weeks, with a maximum of 36 total hours of therapist visit duration. The long-term stage is a follow-up period of up to 2\u2009years during which participants continue self-activated VNS at home using a magnet during functional tasks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Setting:<\/jats:title>\n                    <jats:p>Therapist-activated Paired VNS will be done in the participant\u2019s home.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility Criteria:<\/jats:title>\n                    <jats:p>Participants implanted or scheduled to be implanted commercially with the Vivistim Paired VNS System and assessed as able to receive therapist-activated VNS in the home setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The study will use mobile therapists in the participant\u2019s home instead of a clinic for the initial treatment phase. Paired VNS will be done according to the manufacturer\u2019s instructions for use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The primary endpoint is the number of individuals who complete at least 24\u2009hours of therapy provided in the home setting by a therapist within an 18-week period. Secondary endpoints are change from baseline in assessment measures and patient-reported outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sample Size:<\/jats:title>\n                    <jats:p>Up to 150 participants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/27536351251406666","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:48:28Z","timestamp":1766576908000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Vagus Nerve Stimulation Paired With Rehabilitation in the Home Environment for People With Chronic Post-Stroke Upper Limb Deficits (VNS-REHAB At-Home): Protocol for a Feasibility Trial"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1249-833X","authenticated-orcid":false,"given":"Shannon J.","family":"Doherty","sequence":"first","affiliation":[{"name":"MicroTransponder, Inc., Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-8840","authenticated-orcid":false,"given":"Ruchi","family":"Patel","sequence":"additional","affiliation":[{"name":"NeuroAbilityOT, PLLC, Mooresville, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Spinelli-Guglielmo","sequence":"additional","affiliation":[{"name":"NEUROPATH Physical and Occupational Therapy, PLLC, White Plains, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Zera","sequence":"additional","affiliation":[{"name":"Moxie OT, PLLC, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Antares","sequence":"additional","affiliation":[{"name":"Motion Craft Global, LLC, St. Petersburg, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Diedrich","sequence":"additional","affiliation":[{"name":"Rise and Thrive Mobility Consultants, Tucson, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Adham Hinds","sequence":"additional","affiliation":[{"name":"MicroTransponder, Inc., Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-096X","authenticated-orcid":false,"given":"Navzer D.","family":"Engineer","sequence":"additional","affiliation":[{"name":"MicroTransponder, Inc., Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-8062","authenticated-orcid":false,"given":"Cec\u00edlia N.","family":"Prudente","sequence":"additional","affiliation":[{"name":"MicroTransponder, Inc., Austin, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001303"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3233\/RNN-2004-00282"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-923533"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00475-X"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1390217"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010477"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.022279"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/2396987319855306"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.124.050479"},{"key":"e_1_3_3_11_2","unstructured":"Food and Drug Administration. Postmarket approval (PMA) of MicroTransponder\u00ae Vivistim\u00ae Paired VNSTM System (Vivistim\u00ae System) (P210007A). Published August 27 2021. Accessed June 6 2025. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf21\/P210007A.pdf"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014823"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10749357.2024.2312638"},{"key":"e_1_3_3_14_2","unstructured":"MicroTransponder Inc. MicroTransponder\u00ae Vivistim\u00ae Paired VNSTM System instructions for use. Published 2025. Accessed June 6 2025. https:\/\/www.vivistim.com\/mri-safety-information\/"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2022.09.013"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00280"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1044\/1092-4388(2008\/018)"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000098"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.2340\/1650197771331"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004356-198112000-00001"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.39.6.386"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1545968308331146"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.30.10.213"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000185928.90848.2e"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1961.01710120031004"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","unstructured":"Devlin N Finch AP Parkin D. Guidance to Users of EQ-5D-5L Value Sets. In: Devlin N Roudijk B Ludwig K eds. Value Sets for EQ-5D-5L: A Compendium Comparative Review & User Guide. Springer; 2022. Accessed April 10 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589295\/","DOI":"10.1007\/978-3-030-89289-0_5"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/ptj\/67.2.206"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.004590"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.110.592766"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1545968313491000"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1191\/0269215505cr832oa"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/15459683231186985"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20110009"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2008.02.022"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1545968307305353"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1053\/apmr.2001.18668"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006755.pub2"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/02692155221121015"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/1084822320953836"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056045"}],"container-title":["Advances in Rehabilitation Science and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27536351251406666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/27536351251406666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/27536351251406666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:34:20Z","timestamp":1777599260000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/27536351251406666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"alternative-id":["10.1177\/27536351251406666"],"URL":"https:\/\/doi.org\/10.1177\/27536351251406666","relation":{},"ISSN":["2753-6351","2753-6351"],"issn-type":[{"value":"2753-6351","type":"print"},{"value":"2753-6351","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"27536351251406666"}}